Also known as: locally advanced rectal cancer
Rectal cancer is a malignant neoplasm arising in the rectum, most commonly adenocarcinoma, and is often managed with multimodality treatment including surgery, radiation, and systemic therapy.
Studies in gastroesophageal and locally advanced rectal cancers linked dynamic ctDNA monitoring to treatment response and prognosis. MRD clearance, more than 90% ctDNA declines, and early ctDNA clearance were associated with better outcomes.
A rectal cancer study found hypofractionated radiotherapy increased ISG15+MHC-I+ neutrophils with antigen-presenting capabilities. The report linked the effect to IFN-α/NOD1 signaling and improved anti-PD-1 responses in models.
Colorectal cancer rates are rising 3% annually in adults under 50, prompting expanded screening efforts and new treatment approaches. Recent research shows promise in combination immunotherapy and vaccine strategies for advanced disease.
New research demonstrates that physical activity after cancer diagnosis reduces mortality risk in less common cancers and enhances circadian clock function in tumor tissue, supporting exercise as a therapeutic intervention.
New research shows cancer survivors who exercise reduce their risk of cancer-related death, while expert panel recommends exercise as essential for older cancer patients during and after treatment.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07596732 |
Statewide Unified Network for Remote Intervention of Strength and Exercise |
NOT_YET_RECRUITING | NA |
| NCT07595107 |
Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer |
NOT_YET_RECRUITING | |
| NCT07594925 |
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial |
RECRUITING | PHASE2 |
| NCT07580339 |
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07566559 |
Rectal Cancer Neoadjuvant Therapy-Real World Study |
RECRUITING | |
| NCT07561060 |
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy |
RECRUITING | PHASE1/PHASE2 |
| NCT07552207 |
Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET/MRI for Lymph Node Staging in Rectal Cancer |
NOT_YET_RECRUITING | NA |
| NCT07537998 |
Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial. |
RECRUITING | PHASE2/PHASE3 |
| NCT07528209 |
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer |
RECRUITING | PHASE3 |
| NCT07527520 |
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial |
NOT_YET_RECRUITING | PHASE2 |
